Navigation Links
BioMed Realty, L.P. Announces Closing of Offering of 3.85% Senior Unsecured Notes Due 2016
Date:3/30/2011

SAN DIEGO, March 30, 2011 /PRNewswire/ -- BioMed Realty Trust, Inc. (NYSE: BMR) today announced that its operating partnership subsidiary, BioMed Realty, L.P., completed a public offering of $400 million aggregate principal amount of 3.85% Senior Notes due 2016 (the "Notes").  The Notes are senior unsecured obligations of the operating partnership and are fully and unconditionally guaranteed by BioMed Realty Trust, Inc.  

Interest on the Notes is payable semiannually on April 15 and October 15, beginning October 15, 2011. The Notes will mature on April 15, 2016.  The Notes were issued at 99.365% of the principal amount, with a coupon of 3.85%, to yield 3.99% to maturity.  The operating partnership intends to use the net proceeds from the offering to repay a portion of the outstanding indebtedness under its unsecured line of credit and for other general corporate and working capital purposes.

The registration statement relating to these securities has become effective by rule of the Securities and Exchange Commission.  This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of these securities, nor shall there be any sale of such securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities, blue sky, or other laws of such state or other jurisdiction. Wells Fargo Securities, LLC, KeyBanc Capital Markets Inc., and Morgan Stanley & Co. Incorporated acted as Joint Book Running Managers for the offering.  A final prospectus supplement related to the offering was filed with the Securities and Exchange Commission on March 24, 2011.  A copy of the final prospectus supplement may be obtained by contacting Wells Fargo Securities, LLC, 1525 West W.T. Harris Blvd., NC0675, Charlotte, North Carolina 28262, Attention: Syndicate Operations or by calling toll-free at 1-800-326-5897; KeyBanc Capital Markets Inc., 127 Public Square, 4th Floor, Cleveland, Ohio 44114  or by calling toll-free at 1-866-227-6479; or Morgan Stanley & Co. Incorporated, 180 Varick Street, New York, NY 10014, Attention: Prospectus Department, by calling toll-free at 1-866-718-1649 or by email at prospectus@morganstanley.com.  

About BioMed Realty Trust

BioMed Realty Trust, Inc. is a real estate investment trust (REIT) focused on Providing Real Estate to the Life Science Industry®. The company's tenants primarily include biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry. BioMed owns or has interests in 85 properties, representing 147 buildings with approximately 12.2 million rentable square feet. The company's properties are located predominantly in the major U.S. life science markets of Boston, San Diego, San Francisco, Seattle, Maryland, Pennsylvania and New York/New Jersey, which have well-established reputations as centers for scientific research.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 based on current expectations, forecasts and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties include, without limitation: general risks affecting the real estate industry (including, without limitation, the inability to enter into or renew leases, dependence on tenants' financial condition, and competition from other developers, owners and operators of real estate); adverse economic or real estate developments in the life science industry or the company's target markets; risks associated with the availability and terms of financing, the use of debt to fund acquisitions and developments, and the ability to refinance indebtedness as it comes due; failure to maintain the company's investment grade credit ratings with the ratings agencies; failure to manage effectively the company's growth and expansion into new markets, or to complete or integrate acquisitions and developments successfully; reductions in asset valuations and related impairment charges; risks and uncertainties affecting property development and construction; risks associated with downturns in the national and local economies, increases in interest rates, and volatility in the securities markets; potential liability for uninsured losses and environmental contamination; risks associated with the company's potential failure to qualify as a REIT under the Internal Revenue Code of 1986, as amended, and possible adverse changes in tax and environmental laws; and risks associated with the company's dependence on key personnel whose continued service is not guaranteed. For a further list and description of such risks and uncertainties, see the reports filed by the company with the Securities and Exchange Commission, including the company's most recent annual report on Form 10-K and quarterly reports on Form 10-Q. The company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE BioMed Realty Trust, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Boston University Biomedical Engineers Find Chink in Bacterias Armor
2. Nobel Prize Awarded to Foundation for Biomedical Research Board Member
3. Saladax Biomedicals 5-FU Personalized Chemotherapy Management (PCM(R)) Assay CE Marked for Distribution in the EU
4. Synapse Biomedical Receives FDA Approval of NeuRx Diaphragm Pacing System (DPS)(TM) For Spinal Cord Injury Breathing Applications
5. The Foundation for Biomedical Research Announces Winners of the 7th Annual Michael E. DeBakey Journalism Awards
6. NIH Funds New Wellstone Research Center for Muscular Dystrophy at Boston Biomedical Research Institute
7. OmegaGenesis Unveils Novel Nanotechnology Platform With Broad Biomedical Applications
8. Oramed Pharmaceuticals to Present at the 8th National Life Science & Technology Week ILSI -BIOMED Conference, Israel 2009
9. Subsidiary of Nova Biomedical Completes Acquisition of Assets of CCS Medicals Subsidiary, Sanvita, Inc.
10. Voler Systems President Speaks at BIOMEDevice San Jose
11. Nominations Open for the 2010 Dr. Paul Janssen Award for Biomedical Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2017)... , July 11, 2017  Bayer has awarded grants ... countries as part of its prestigious Bayer Hemophilia Awards Program ... of Philadelphia and Uniformed Services University ... are among the winners. Grant recipients were announced last night ... Hemostasis (ISTH) 2017 Congress, Berlin, Germany . ...
(Date:7/11/2017)... 2017  Sysmex America, Inc., a leading provider ... as well as middleware information systems technology, today ... quality assurance easier and more risk free than ... for the innovation that it delivers to the ... assurance processes to a new level with automated, ...
(Date:7/11/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ... on the development of oral drug delivery systems, announced ... has agreed to schedule an End-of-Phase II meeting with ... its oral insulin capsule ORMD-0801 in the treatment of ... and secondary endpoints by indicating a statistically significant lowering ...
Breaking Medicine Technology:
(Date:7/20/2017)... (PRWEB) , ... July 20, 2017 , ... ... law firm headquartered in Houston, is pleased to announce their expansion to the ... affordable housing experience, directors Alysse Hollis and Ronald Bell, and of counsels, John ...
(Date:7/20/2017)... ... ... Team Type 1 Foundation, a nonprofit organization pursuing a global mission of ... up with a Microsoft Corp. employee-led hackathon team for the 2017 Microsoft One Week ... Type 1’s mission overlaps seamlessly with Microsoft’s mission to empower every person and every ...
(Date:7/20/2017)... ... July 20, 2017 , ... Girl Up Campaign Director, Melissa ... legislation in support of providing girls access to education in refugee settings. In May, ... “Protecting Girls’ Access to Education in Vulnerable Settings Act.” Yesterday, companion legislation was ...
(Date:7/20/2017)... ... July 20, 2017 , ... TCGRx announced today ... existing adherence automation lines. The ATP® Mini and InspectRx® Mini are ... standard products, but at a size and price point that can help pharmacies ...
(Date:7/20/2017)... ... July 20, 2017 , ... With ... 2014, top travel insurance solution company VisitorsCoverage Inc. has launched TMQuotes, a new ... international travel insurance products online, under their own brand. The online marketplace bridges ...
Breaking Medicine News(10 mins):